Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Oncology. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN114524701B reveals a novel organocatalytic route for N-N axis chiral pyrroles with high cytotoxicity, offering cost-effective API intermediate manufacturing solutions.
Patent CN114524701B reveals a novel chiral phosphoric acid catalyzed route for N-N axis chiral pyrroles with high enantioselectivity and cytotoxic activity.
Patent CN112028841A reveals a catalyst-free visible light method for high-yield quinoxalinone synthesis, offering significant cost reduction in pharmaceutical intermediate manufacturing.
Patent CN108794412B details a high-yield base-promoted cyclization for 4,5-diaryl-1,2,3-triazoles, offering significant cost reduction in API manufacturing and superior purity profiles.
Patent CN111675662B reveals a cost-effective FeCl3-catalyzed route for high-purity quinazolinone derivatives, offering significant supply chain advantages.
Patent CN109096357B details a novel 3-step synthesis of thioether-cholesterol naphthalimides, offering a reliable pharmaceutical intermediate supplier solution with optimized scalability.
Patent CN111675662B reveals a novel FeCl3-catalyzed route for 2-trifluoromethyl quinazolinones, offering significant cost reduction in API manufacturing and scalable production.
Patent CN112920053B details a mild, high-yield route for chiral amines used in asthma and oncology drugs, offering significant supply chain stability.
Patent CN112920053B reveals a scalable, high-purity route for chiral amines used in asthma and oncology APIs, offering significant cost and safety advantages.
Discover a novel metal-free organocatalytic route to axially chiral 1-aryl indoles. High optical purity, mild conditions, and scalable synthesis for glioma inhibitors.
Patent CN112920173A details a chiral phosphoric acid catalyzed synthesis of cytotoxic chroman derivatives, offering high enantioselectivity and scalable manufacturing for oncology drug development.
Novel chiral phosphoric acid catalysis enables high-yield, high-ee synthesis of anticancer intermediates, ensuring cost-effective and reliable supply chain solutions.
Novel chiral phosphoric acid catalyzed synthesis of axially chiral indole-naphthalene compounds. High enantioselectivity, mild conditions, scalable for API manufacturing.
Patent CN111675662B reveals a cost-effective FeCl3 catalyzed route for 2-trifluoromethyl quinazolinones, offering reliable pharmaceutical intermediate supply.
Patent CN112321593B reveals a cost-effective cobalt-catalyzed carbonylation route for indolo[1,2-a]quinazolin-6(5H)-ones, offering significant supply chain advantages.
Novel chiral phosphoric acid catalyzed synthesis of N-N axis chiral bisindoles with high enantioselectivity. Ideal for anticancer drug development and cost-effective API manufacturing.
Patent CN119320392A details a green catalytic route for Rucaparib. This report analyzes cost reduction in API manufacturing and supply chain reliability for procurement teams.
Patent CN112920173A details a mild chiral phosphoric acid catalyzed synthesis of cytotoxic chroman derivatives, offering high enantioselectivity and scalable API intermediate manufacturing.
Discover a novel Cytosine-based route for Palbociclib parent nucleus. Enhance purity to >99% and reduce costs in pharmaceutical manufacturing with this scalable process.
Advanced 6-step preparation method for CDK4/6 inhibitor SHR6390. Delivers high purity, mild conditions, and cost reduction in API manufacturing for global supply chains.